Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451033 | 0.73 | SMN1; SMN2 (0.75) | MAPTSMN1; SMN2NPSR1P2RX4P2RX1 | |
| SCHEMBL22600935 | 0.69 | ALDH1A1 (0.34) | NPSR1P2RX4ALDH1A1 | |
| SCHEMBL30869549 | 0.69 | MAPT (0.37) | MAPTSMN1; SMN2NPSR1P2RX4P2RX1 | |
| Acetic Acid SCHEMBL10626222 | 0.66 | P2RX4 (0.47) | MAPTSMN1; SMN2NPSR1P2RX4 | |
| SCHEMBL23565774 | 0.64 | — | — | |
| Acetic Acid SCHEMBL29701132 | 0.64 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1 | |
| Acetamide SCHEMBL28954498 | 0.64 | ATM (0.54) | MAPTSMN1; SMN2NPSR1P2RX4 | |
| SCHEMBL3423393 | 0.64 | AHR (0.43) | ALDH1A1TP53HTT | |
| SCHEMBL25137434 | 0.64 | ALDH1A1 (0.34) | ALDH1A1TP53HTT | |
| SCHEMBL24390084 | 0.63 | P2RX4 (0.40) | MAPTSMN1; SMN2NPSR1P2RX4P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4583868-A2 | DYNAMIN ACTIVATORS | Walden Biosciences, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054661-A2 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | DNM1, DNM1L, DNM2 | MAPT 2165/4885SMN1; SMN2 1915/4885NPSR1 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.